Jay Traverse, MD, principal investigator of LateTIME, spoke with Cardiovascular Business about the findings of his 2011 AHA late-breaking clinical trial.

ORLANDO, Fla.—Jay Traverse, MD, principal investigator of LateTIME, a trial presented Nov. 14 at the American Heart Association (AHA) conference, spoke with Cardiovascular Business about the trial, in addition to the potential role of cell therapy in cardiovascular care.

As part of the National Heart, Lung and Blood Institute–sponsored Cardiovascular Cell Therapy Research Network, Traverse and his colleagues compared the effects of bone marrow mononuclear cells (BMC) delivery in patients with STEMI at three versus seven days post-MI. The LateTIME trial was designed to explore whether delayed BMC delivery two to three weeks following MI could improve global and regional left ventricular function.

While the findings from the trial were negative, Traverse spoke about the uses in the future. 

This video was conducted collaboratively with ClinicalTrialResults.org.